Cookies
Explanation about the cookies that we use to enhance the experience of your website visit.

Which cookies do we use? And why?

This site uses cookies (and similar technologies) to save your preferences, so that we can offer a personalised, thus better, experience. The information that is saved in these cookies is encrypted and can only be read (again) by this website. And this, only when you are active on the site.

At the moment, we use the following cookies:

  • XSRF-token: We generate automatically an XSRF (sometimes also called CSRF) “token” for each active user session that is managed by our application. This token is used to check whether the verified user is really the one that sends requests to the application. The token is generated automatically and added to each page request. The retention period is 1 minute.
  • XXXXXXX_session: We use a _session “token” to be able to couple a user to his/her session data. The cookie only contains an encrypted value that enables us to to link the user (from his/her browser) to his/her session data, that is kept on the server, and his/her session preferences (if any, logged in or not). The retention period is 1 day.
  • remember_web_YYYYYYY: This token is used to save a user's choice to "remember him/her" so that it is no longer needed to log in on each visit again. The token is saved at the moment a user checks the "remember me" option at login time. The retention period is 5 years.

The first two cookies are essential cookies (to protect forms and to keep session information for logged in users), for which we don't need your permission. The last cookie is only saved when a user chooses for this option.

We don't use cookies of third parties (like Google Analytics of Facebook,…). Because we don't have an impact on the reach of their cookie policy statements, nor on the concrete content of their cookies.

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.